3rd Annual Biosimilars North America Conference

Biosimilars North America

16th November to 17th November 2016,

 Renaissance Woodbridge Hotel, Iselin, New Jersey, USA

$400 early bird ending on 30^th June. $100 early bird ending on 30^th September.

 

Building on previous success, SMi proudly announces the return of 3rd Annual Biosimilars North America conference to New Jersey in November 2016!

 

This meeting will update you with the latest market developments and regulatory updates to ensure you stay at the forefront of this evolving market!

 

Join us today to:

•Hear latest regulatory updates for smooth and speedy approval

•Learn successful biosimilar case studies to reshape your business model

•Dissect regional market growth opportunities - where should you go next?

•Network with like-minded senior experts and engage in interactive debates

 

Unrivalled speaker line up in 2016 includes:

- Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals

- Gustavo Grampp, Ph.D., Director R&D Policy - Biosimilars, Amgen Inc.

- Andrew Simpson, Scientifi c Director, Orygen Biotechnologia S/A

- Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US

- Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfizer Inc.

- Molly Burich, Associate Director, Public Policy – Biosimilars, Pipeline, Reimbursement, Boehringer Ingelheim Pharmaceuticals, Inc

- Catherine Godrecka-Bareau, Director Strategy & Portfolio Management, Biosimilars, EMD Serono , and many more!

 

Plus 2 interactive pre-conference workshops:

A: Leveraging Successful Patient Recruitment & Retention Strategies in Biosimilars Research.
(Led by UBC – An Express Scripts Company).

B: Biosimilars: Considerations for Optimizing Access and Price.
(Led by MKTX Market Access Solutions, LLC).

 

For more information visit: www.biosimilars-northamerica.com/beq    

 

To register get in touch with Fateja Begum: +44 (0) 20 7827 6184 or fbegum@smi-online.co.uk